ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)
This study evaluated the safety of ENX-104 for people with depression.
Understand this study
What did researchers investigate?
This study evaluated the safety of ENX-104 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Blackpool and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- Engrail Therapeutics INC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07253324
- Official title
Show the full official title
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-104 in Participants With Major Depressive Disorder With Anhedonia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Blackpool · Prescot · Cannock
1 more locations
- Manchester
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of ENX-104 for people with depression.
Who is behind this study?
The study sponsor is Engrail Therapeutics INC.
Did this study involve medication?
Yes. The study involved medication, including ENX-104 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
